Preprint Article Version 1 This version is not peer-reviewed

Three-Year Analysis of Adjuvant Therapy in Postoperative Melanoma including Acral and Mucosal Subtypes

Yusuke Muto
,
Yumi Kambayashi
,
Hiroshi Kato
,
Satoru Mizuhashi
,
Takamichi Ito
,
Takeo Maekawa
,
Shoichiro Ishizuki
,
Hiroshi Uchi
,
Shigeto Matsushita
,
Yuki Yamamoto
,
Koji Yoshino
,
Yasuhiro Fujisawa
,
Ryo Amagai
,
Kentaro Ohuchi
,
Akira Hashimoto
,
Satoshi Fukushima
,
Yoshihide Asano
,
Taku Fujimura¹
*
Version 1 : Received: 1 July 2024 / Approved: 1 July 2024 / Online: 2 July 2024 (10:51:38 CEST)

How to cite: Muto, Y.; Kambayashi, Y.; Kato, H.; Mizuhashi, S.; Ito, T.; Maekawa, T.; Ishizuki, S.; Uchi, H.; Matsushita, S.; Yamamoto, Y.; Yoshino, K.; Fujisawa, Y.; Amagai, R.; Ohuchi, K.; Hashimoto, A.; Fukushima, S.; Asano, Y.; Fujimura¹, T. Three-Year Analysis of Adjuvant Therapy in Postoperative Melanoma including Acral and Mucosal Subtypes. Preprints 2024, 2024070117. https://doi.org/10.20944/preprints202407.0117.v1 Muto, Y.; Kambayashi, Y.; Kato, H.; Mizuhashi, S.; Ito, T.; Maekawa, T.; Ishizuki, S.; Uchi, H.; Matsushita, S.; Yamamoto, Y.; Yoshino, K.; Fujisawa, Y.; Amagai, R.; Ohuchi, K.; Hashimoto, A.; Fukushima, S.; Asano, Y.; Fujimura¹, T. Three-Year Analysis of Adjuvant Therapy in Postoperative Melanoma including Acral and Mucosal Subtypes. Preprints 2024, 2024070117. https://doi.org/10.20944/preprints202407.0117.v1

Abstract

Background Adjuvant therapy has improved the clinical prognosis for postoperative melanoma patients. but the long-term efficacy of acral and mucosal types has not been fully evaluated in previous trials. This study aimed to assess the 3-year recurrence-free survival (RFS) and overall survival (OS) of melanoma treated with anti-PD-1antibody (Ab) or the combination of dabrafenib and trametinib. Methods We retrospectively analyzed both the 3-year recurrence-free survival (RFS) and overall survival (OS). Results The median RFS was 18.4 months, with a range of 0.69 to 36 months. The 3-year RFS of the acral and mucosal types was 28.1% and 38.5%, respectively. Baseline tumor thickness (TT) and acral type were associated with the RFS in subgroup analysis. Moreover, we classified 104 acral and non-acral cutaneous patients into the anti-PD-1 Abs or dabrafenib plus trametinib combined therapies cohort in multiple analyses. The acral subtype and TT were detected as important prognostic factors. In the 3-year OS, only tumor ulceration was associated with the OS in both univariate and multiple analyses. Conclusion This study suggests that both acral and mucosal types in the adjuvant setting are less effective than non-acral cutaneous melanoma at the 3-year RFS.

Keywords

Acral, mucosal, anti-PD-1 Abs, BRAF plus MEK inhibitors, adjuvant therapy

Subject

Biology and Life Sciences, Immunology and Microbiology

Copyright: This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Download PDF Download Supplementary

Comments (0)

We encourage comments and feedback from a broad range of readers. See criteria for comments and our Diversity statement.

Leave a public comment
Send a private comment to the author(s)
* All users must log in before leaving a comment
Views 0
Downloads 0
Comments 0
Metrics 0
Get PDF Supplementary Files Cite Share 0
Bookmark BibSonomy Mendeley Reddit Delicious
×
Alerts
Notify me about updates to this article or when a peer-reviewed version is published.
We use cookies on our website to ensure you get the best experience.
Read more about our cookies here.